Back to News
Market Impact: 0.2
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
Source: GlobeNewswire
Healthcare & Biotech
A Phase 2 clinical trial will evaluate the efficacy and safety of an unspecified treatment in participants with surgically diagnosed endometriosis and moderate-to-severe endometriosis-associated pain. The report provides no efficacy data, safety results, enrollment figures, or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
More News
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Bon Secours affiliate sweetens bid for Surgery Partners to up to $6 billion
- CorMedix stock gains as Heron deal adds four products
- Rezolute at Guggenheim: FDA progress lifts rare-disease hopes
- Hims & Hers earnings up next: Can GLP-1 boom drive profit?
- Harrow earnings on deck as investors eye profitability return